Post-earnings recap
Reported
Fri, Aug 6, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Twist Bioscience's earnings report showed a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue figures and guidance left investors uncertain about the company's short-term performance. This reaction reflects broader concerns about the company's ability to navigate current market challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | -8.32% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current market conditions impacting performance. They emphasized a commitment to long-term strategies.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on long-term growth despite current challenges.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—